Mechanisms ID'd for Curcumin Resensitization of Cancer Cells

Share this content:
Mechanisms ID'd for Curcumin Resensitization of Cancer Cells
Mechanisms ID'd for Curcumin Resensitization of Cancer Cells

WEDNESDAY, Aug. 2, 2017 (HealthDay News) -- Curcumin can resensitize chemoresistant pancreatic ductal adenocarcinoma (PDAC) cells through inhibition of the polycomb repressive complex 2 (PRC2)-PVT1-c-Myc axis, according to a study published online July 17 in Carcinogenesis.

Noting that curcumin can overcome de-novo chemoresistance and resensitize tumors to chemotherapeutic agents, Kazuhiro Yoshida, M.D., from the Baylor University Medical Center in Dallas, and colleagues examined the underlying mechanisms for curcumin-mediated chemosensitization.

The researchers reported the resensitization of chemoresistant PDAC cells by curcumin through inhibition of the PRC2-PVT1-c-Myc axis. Curcumin sensitized chemoresistant cancer cells inhibited expression of the PRC2 subunit enhancer of zeste homolog-2 and its related long non-coding RNA PVT1 using gemcitabine-resistant PDAC cell lines. Curcumin also prevented spheroid formation and down-regulated several genes driving self-renewal. In vitro findings were confirmed in a xenograft mouse model, with inhibition of gemcitabine-resistant tumor growth by curcumin.

"Overall, this study establishes clinical relevance for combining curcumin with chemotherapy to overcome chemoresistance in PDAC," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths